Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis

Trial Profile

Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Sep 2016

At a glance

  • Drugs NDV 3 (Primary) ; Aluminium hydroxide
  • Indications Vulvovaginal candidiasis
  • Focus Adverse reactions
  • Sponsors NovaDigm Therapeutics
  • Most Recent Events

    • 21 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 15 Aug 2016 Initial results from this trial were presented at the Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology in Annapolis, as reported by a NovaDigm Therapeutics media release.
    • 15 Aug 2016 Results published in the NovaDigm Therapeutics Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top